Paradigms and perspectivesAntibody-mediated neuropsychiatric disorders
References (10)
- et al.
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis
Lancet Neurol
(2018) - et al.
A clinical approach to diagnosis of autoimmune encephalitis
Lancet Neurol
(2016) - et al.
Acute encephalitis in immunocompetent adults
Lancet
(2019) - et al.
Potassium channel antibodies in two patients with reversible limbic encephalitis
Ann Neurol
(2001) - et al.
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma
Ann Neurol
(2007)
There are more references available in the full text version of this article.
Cited by (7)
Paraneoplastic/autoimmune myelopathies
2024, Handbook of Clinical NeurologyHow do we forecast tomorrows’ transfusion: Non-transfusional hemotherapy
2023, Transfusion Clinique et BiologiqueThe immunopathogenesis of narcolepsy type 1
2024, Nature Reviews ImmunologyIs it psychosis, or an autoimmune encephalitis?
2022, Current Psychiatry
Disclosure of potential conflict of interest: J. Dalmau holds patents for the use of Ma2, NMDAR, GABAbR, GABAaR, DPPX and IgLON5 as autoantibody tests; receives royalties related to autoantibody tests from Athena Diagnostics and Euroimmun, Inc; and receives research support from SAGE Therapeutics, Inc. F. Graus holds a patent for the use of IgLON5 as an autoantibody test.
© 2021 American Academy of Allergy, Asthma & Immunology